

Ethical approval

Not required.

Patient consent

Not required.

Hendrik Naujokat*

Jörg Wiltfang

Department of Oral and Maxillofacial
Surgery, University Hospital of
Schleswig-Holstein, Campus Kiel, Kiel,
Germany

*Address: Hendrik Naujokat, Department
of Oral and Maxillofacial Surgery, Uni-
versity Hospital of Schleswig-Holstein,
Campus Kiel, Arnold-Heller-Straße 3,
24105 Kiel, Germany. Tel.: +49 (0)431
500 26140, Fax: +49 (0)431 500 26006.
E-mail address: naujokat@mkg.uni-kiel.
de (H. Naujokat)

Reference

1. Naujokat H, Möller B, Terheyden H, Birkenfeld F, Caliebe D, Krause MF, Fischer-Brandies H, Wiltfang J. Tongue reduction in Beckwith-Wiedemann syndrome: outcome and treatment algorithm. *Int J Oral Maxillofac Surg* 2019;**48**:9–16. <http://dx.doi.org/10.1016/j.ijom.2018.07.008>. Epub 2018 July 26.

Danger of highlighting the use of coxibs in daily dental practice

We read the valuable research by Isola et al. on the efficacy of celecoxib and ibuprofen for postoperative pain, swelling, and mouth opening after the surgical removal of impacted third molars with great interest¹. Nevertheless, we have some concerns regarding the cardiovascular adverse effects of COX-2 inhibitors.

As mentioned by Isola et al.¹, the surgical removal of third molars is one of the most common surgeries in daily dental practice. Pain, swelling, and restriction in mouth opening are the main problems in the postoperative period that the dental practitioner has to deal with. Considering the gastrointestinal, hematopoietic, and renal adverse effect profile of COX-1 inhibition, the formulation of non-steroidal anti-inflammatory drugs with relative COX-2 selectivity became a highly desirable target during the 1990s². However, studies in the first half of this decade revealed adverse effects of COX-2 inhibition on the cardiovascular system, includ-

ing an increased risk of myocardial infarction, exacerbation of stable congestive heart failure, and worsening high blood pressure³. Randomized trials and meta-analyses confirmed these findings, triggering a red flag for a potential cardiovascular safety issue with coxibs; this also led to the withdrawal of some of the COX-2 inhibitors from the market by the US Food and Drug Administration⁴. Recent studies have also recommended caution in prescribing COX-1 and 2 inhibitors for patients with existing cardiovascular conditions, until more evidence for safety via randomized trials is available⁵.

As suggested by Isola et al.¹, the most remarkable finding of their study is that treatment with celecoxib decreased the incidence and severity of postoperative pain following third molar surgery. This conclusion is very important and could affect the clinical behaviour of dental clinicians. We believe that when selecting celecoxib after dental surgery, its adverse effects must be considered. Therefore, the possible side effects of COX-2 inhibitors should have been emphasized in the text by the authors.

Funding

None.

Competing interests

None.

Ethical approval

Not applicable.

Patient consent

Not applicable.

A. Gülses*

Y. Açil

J. Wiltfang

Department of Oral and Maxillofacial
Surgery, University Hospital Schleswig-
Holstein, Campus Kiel, Kiel, Germany

*Address: Aydin Gülses, Department of
Oral and Maxillofacial Surgery, Univer-
sity Hospital Schleswig-Holstein, Campus
Kiel, Arnold-Heller-Straße 3, 24105 Kiel,
Germany. Tel.: +49 15147509544;
Fax: 0431 500 26164.

E-mail address: aguelses@mkg.uni-kiel.de

(A. Gülses)

References

1. Isola G, Matarese M, Ramaglia L, Cicciù M, Matarese G. Evaluation of the efficacy of celecoxib and ibuprofen on postoperative pain, swelling, and mouth opening after surgical removal of impacted third molars: a randomized, controlled clinical trial. *Int J Oral Maxillofac Surg* 2019;(March). <http://dx.doi.org/10.1016/j.ijom.2019.02.006>. pii:

S0901-5027(19)30070-0. [Epub ahead of print].

2. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitz Gerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. *Proc Natl Acad Sci U S A* 1999;**96**:272–7.
3. Amer M, Bead VR, Bathon J, Blumenthal RS, Edwards DN. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. *Cardiol Rev* 2010;**18**:204–12.
4. Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. *Br J Clin Pharmacol* 2016;**82**:957–64.
5. Husband M, Mehta V. Cyclo-oxygenase-2 inhibitors. *Contin Educ Anaesth Crit Care Pain* 2013;**13**:131–5.

In response to Letter to the Editor “Danger of highlighting the use of coxibs in daily dental practice”

We appreciate the Letter to the Editor by Gülses et al. in response to our article entitled “Evaluation of the efficacy of celecoxib and ibuprofen on postoperative pain, swelling, and mouth opening after surgical removal of impacted third molars: a randomized, controlled clinical trial”¹. We also thank these authors for their recognition of the results of our randomized controlled clinical trial.

The comments raised by these authors regarding the adverse effects of COX-2 inhibition on the cardiovascular system, including the increased risks of myocardial infarction and disturbance of blood pressure, are well taken. However, some elaboration is in order.

The surgical removal of third molars is one of the most common surgical interventions in daily dental practice. Previous studies have demonstrated that celecoxib used at a dose ranging between 120 mg and 200 mg is efficient in the reduction of early stage acute pain and perioperative symptoms following third molar surgery^{2,3}.

During the last few decades, COX-2 selective inhibitors were introduced to provide the anti-inflammatory effects of non-steroidal anti-inflammatory drugs (NSAIDs) with less gastrointestinal toxicity. However, the first studies on COX-2 inhibitors, used for a wide range of conditions such as osteoarthritis and rheumatoid arthritis, found an increased risk of cardiovascular disease (CVD)